Global Liver Diseases Therapeutics Market is expected to grow at a CAGR of 8.2% during the forecast period 2020-2027
A new research report published by Fior Markets with the title Liver Diseases Therapeutics Market by Product (Corticosteroids, Immunoglobulins, Targeted Therapy, Chemotherapy, Immunosuppressants, Vaccines, Antiviral Drugs), End-User (Ambulatory Surgery Centers, Hospitals, Specialty Clinics), Region, Global Industry Analysis, Market Size, Share, Growth, Trends, and Forecast 2020 to 2027.
The global liver diseases therapeutics market is expected to grow from USD 11.10 billion in 2019 to USD 20.86 billion by 2027, at a CAGR of 8.2% during the forecast period 2020-2027. Asia Pacific is expected to have a significant share in the market over the forecast period. It is due to the increased prevalence of hepatocellular carcinoma and hepatitis as well as favourable government initiatives regarding drug price adjustment. Also, the presence of infrastructure related to healthcare needs is contributing in the growth of the liver diseases therapeutics market.
NOTE: Our analysts monitoring the situation across the globe explains that the market will generate remunerative prospects for producers post COVID-19 crisis. The report aims to provide an additional illustration of the latest scenario, economic slowdown, and COVID-19 impact on the overall industry.
DOWNLOAD FREE SAMPLE REPORT: https://www.fiormarkets.com/report-detail/418531/request-sample
Key players in the liver diseases therapeutics market are Astellas Pharma Inc., Gilead Sciences, F. Hoffmann-La Roche Ltd., Novartis AG, Takeda Pharmaceuticals, Watson Pharmaceuticals, Abbott Laboratories, GlaxoSmithKline plc, Sanofi S.A., Valeant Pharmaceuticals, Merck & Co., Inc., Pfizer Inc and Bristol-Mayers Squibb. Key companies are focusing more on growth strategies, such as product approvals and product launches. Key players are emphasizing on clinical trials in order to increase the clinical evidences. For the treatment of thrombocytopenia, GSK announced the approval of PROMACTA in patients having chronic hepatitis.
The product segment includes corticosteroids, immunoglobulins, targeted therapy, chemotherapy, immunosuppressants, vaccines and antiviral drugs. Antiviral drugs segment is expected to show significant growth over the forecast period. It is due to the presence of pipeline drugs. The market growth is attributed to partnerships, strategic alliances between the key companies as well as a rise in the awareness regarding healthcare in emerging economies. The end-user segment includes ambulatory surgery centres, hospitals and specialty clinics. Hospital segment is expected to have a significant growth over the forecast period. Various types of treatments are facilitated in the hospitals by providing adequate machines and infrastructure required in a specific therapy. Also, hospitals are more reliable in complex therapies as it has necessary man-force and emergency services along with enhanced treatment facilities.
Liver diseases therapeutics market is expected to have a rapid growth over the forecast period. It is due to various factors such as increasing government initiatives, improper diet, growing awareness regarding advanced products, an increase in consumption of alcohol and a rise in the prevalence of liver diseases. Liver disease can be result into unforeseen death due to viral hepatitis, complications of cirrhosis and hepatocellular carcinoma. Favourable initiatives by the government results in an increased awareness related to liver diseases along with its prevention and cure.
About the report:
The global liver diseases therapeutics market is analyzed on the basis of value (USD Billion), volume (K Units), export (K Units), and import (K Units). All the segments have been analyzed on global, regional and country basis. The study includes an analysis of more than 30 countries for each segment. The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The study includes porter’s five forces model, attractiveness analysis, raw material analysis, and competitor position grid analysis.
Customization of the Report:
The report can be customized as per client requirements. For further queries, you can contact us on firstname.lastname@example.org or +1-201-465-4211. Our executives will be pleased to understand your requirements and offer you the best-suited reports.
- CDN Newswire